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Background. BK virus–associated hemorrhagic cystitis (BKV-HC) is a severe complication after allogeneic
hematopoietic stem cell transplantation (HSCT), but antiviral treatment for this condition has not been evaluated.
Methods. We conducted a retrospective survey on the safety and outcome of cidofovir treatment for patients
with BKV-HC in centers affiliated with the European Group for Blood and Marrow Transplantation.
Results. From 1 April 2004 to 31 December 2007, 62 patients received a diagnosis of BKV-HC after a median
interval of 35 days after HSCT (range, 3–577 days). Fifty-seven patients (92%) received intravenous cidofovir,
whereas 5 patients received cidofovir intravesically. Complete response (CR) was recorded in 38 (67%) of 57
patients with HC treated with intravenous cidofovir, whereas partial response (PR) was documented in 7 patients
(12%). CR was documented in 3 patients and PR in 1 patient with HC treated with intravesical cidofovir. A
reduction of 1–3 logs in BKV load was documented in 8 of the 10 patients achieving CR. Mild-to-moderate toxic
effects were recorded in 18 of 57 patients who received intravenous cidofovir administration. In a multivariate
analysis, the factors significantly associated with response to cidofovir were the stem cell source ( ) and thePp .01
use of total body irradiation ( ). After a median follow-up of 287 days, overall survival and total treatment-Pp .03
related mortality rates were 63% and 40% for patients achieving CR, compared with 14% and 72% for patients
with PR or no response to cidofovir, respectively ( and , respectively).P ! .001 Pp .001
Conclusions. Cidofovir may be a potentially effective therapy for BKV-HC, but evidence supporting its use
requires randomized controlled trials.
Polyomavirus hominis type 1, called BK virus (BKV),
has been associated with the occurrence of hemorrhagic
cystitis (HC) in patients undergoing hematopoietic
stem cell transplantation (HSCT) [1–6]. In most cases,
BKV-HC occurs in the early postengraftment period,
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and it more frequently affects patients undergoing al-
logeneic than autologous HSCT. Accordingly, the al-
loimmune reaction of acute graft-versus-host disease
(GVHD), or its treatment, may play a key role in the
pathogenesis of BKV-HC [7–11].
Supportive measures have been the standard of care
for many years, but new insights into the pathogenesis
of late-onset HC have initiated the demand for a spe-
cific treatment inhibiting BKV replication [10–12]. Ci-
dofovir is an acyclic nucleoside analogue that in in vitro
studies demonstrates a broad range of antiviral activity,
including BKV [13–15]. This drug is licensed for the
treatment of cytomegalovirus retinitis in patients with
AIDS and for ganciclovir-resistant cytomegalovirus in-
fections, but encouraging case series may suggest its use
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for BKV-associated nephropathy in renal transplant recipients
[16, 17]. Given its potential for nephrotoxicity, limited series
at single institutions have been reported on the treatment of
BKV-HC, so the paucity of data has left the indications for its
use in HSCT recipients unresolved [6, 18, 19]. We report the
results of a retrospective study on the safety and efficacy of
cidofovir in the treatment of BKV-HC after allogeneic HSCT.
MATERIALS AND METHODS
The study was approved by the Scientific Committee of the
European Group for Blood and Marrow Transplantation–In-
fectious Disease Working Party (EBMT-IDWP) and was pre-
sented at the IDWP session of the annual EBMT congress in
Lyon, France, in 2007. A call for participation was subsequently
sent to all centers by the EBMT central office. Data collection
and processing were in accordance with standards at every cen-
ter for patient confidentiality and good clinical practice. Trans-
plantation protocols were approved by the local institutional
review board, and all parents or patients gave their informed
consent before HSCT.
Patient recruitment. Patients were eligible for the study if
they had received cidofovir treatment for BKV-HC diagnosed
after an allogeneic HSCT. BKV-HC was classified with regard
to the variable degree of macroscopic hematuria, according to
the grading score proposed by Droller et al. [20] and others:
grade II, macroscopic hematuria; grade III, macroscopic he-
maturia with clots; and grade IV, macroscopic hematuria with
renal or bladder dysfunction [6], with symptoms of cystitis and
demonstration of concurrent BKV replication in urine or blood
[3, 5, 6]. We excluded patients receiving cidofovir for HC not
related to BKV infection or preemptive treatment for asymp-
tomatic BK viruria and viremia with or without microscopic
hematuria (i.e., grade I HC). Data on concurrent infective
causes of cystitis were collected, but they did not represent a
reason for exclusion from the study.
Patient management. All patients were treated in high-
efficiency particulate–filtered air rooms during the neutropenic
phase, and standard measures were adopted to prevent or treat
toxic effects to the organ, GVHD, and infectious complications
[21]. Hyperhydration, forced diuresis, and urine alkalinization
were used in all patients during the conditioning regimen as
preventive measures for drug-related chemical cystitis, whereas
mercaptoethane sodium sulfonate was given to patients re-
ceiving cyclophosphamide.
Polymorphonuclear cell and platelet engraftment were de-
fined as the first of 3 and 7 consecutive days on which poly-
morphonuclear cell and platelet counts exceeded cells/90.5 10
L and platelets/L, respectively. BKV replication in both950 10
urine and plasma was determined by polymerase chain reaction.
The timing and frequency of testing were at the discretion of
the treating physician.
Standard criteria were used to define transplantation-related
mortality (TRM), infections, and acute or chronic GVHD [22–
25]. Only the patients who had polymorphonuclear cell en-
graftment or survived at least 100 days after HSCT were con-
sidered assessable for acute and chronic GVHD, respectively.
The remission status of the underlying malignant disease was
classified as controlled if the patient was in complete remission,
partial remission, or chronic phase (only for patients with
chronic myeloid leukemia) or had a diagnosis of refractory
anemia; in the remaining patients, the underlying malignant
disease was defined as uncontrolled. Complete response (CR)
was defined as a complete resolution of HC after cidofovir
treatment, whereas partial response (PR) was defined as a sig-
nificant improvement of symptoms of HC but persistence of
gross hematuria. Failure was considered as no improvement or
worsening of HC.
Statistical analysis. The follow-up data were analyzed as
of 31 December 2007. Where appropriate, patient character-
istics were compared using x2 or Fisher’s exact test for cate-
gorical variables [26]. TRM and overall survival (OS) were
calculated from the date of HSCT to the date of any nonrelapse
death or any death due to any cause, respectively, or to the
date of latest follow-up. TRM was estimated by the cumulative
incidence method, with death from relapse being the competing
event [27]. OS was estimated by the Kaplan-Meier method.
Host- or HSCT-related characteristics were assessed in the anal-
ysis of prognostic factors for efficacy of cidofovir therapy. Mul-
tivariate analysis was performed with SAS statistical software,
version 9.1 (SAS Institute), and a logistic regression model;
hazard ratios, 95% confidence intervals (CIs), and 2-sided P
values were calculated [28]. The level of statistical significance
was set at .ap .05
RESULTS
From 1 April 2004 to 31 December 2007, 62 episodes of BKV-
HC treated with cidofovir were recorded in 62 patients from
17 EBMT centers. Nine patients were recently described in a
single case series [29, 30]. The median number of episodes was
3 per center (range, 1–12). In 2 episodes the administration of
cidofovir was also indicated for concurrent adenovirus infec-
tion. There were 46 males (74%) and 16 females (26%), with
a median age of 15.9 years (range, 2.5–62.3 years) at diagnosis
of BKV-HC. The underlying medical diagnosis was acute leu-
kemia in 36 patients (58%), chronic myeloid leukemia in 10
(16%), non-Hodgkin lymphoma in 5 (8%), other malignant
diseases in 3 (5%), and nonmalignant disease in 8 (13%). In
patients with malignant diseases, the remission status was de-
fined as controlled in 45 (83%) and uncontrolled in 9 (17%).
Thirty-three episodes (53%) occurred in patients younger than
18 years.
Characteristics of HC. HC was diagnosed at a median in-
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Table 1. Summary of therapy with cidofovir.
Variable Finding
Intravenous cidofovir
Proportion (%) of treated patients 57/62 (92)
Median no. of doses (range) 4 (1–15)
First dose, median mg/kg (range)a 5 (0.5–5.7)
Patients experiencing toxic effects of cidofovir, proportion (%) 18/57 (32)
No. of patients experiencing toxic effects in the kidney 17







Proportion (%) of patients treated 5 (8)
Median no. of treatments (range) 4 (1–5)
Median first dose, mg (range) 150 (50–200)
Toxicity of cidofovir No
NOTE. WHO, World Health Organization.
a Thirteen patients received cidofovir, 0.5–1 mg/kg; and 44 patients received cidofovir, 3–5
mg/kg.
terval of 35 days (range, 3–577 days) after HSCT. Fifty-two
(84%) of 62 episodes occurred after day 15, whereas 55 episodes
(89%) were diagnosed by day 100 after HSCT. Severity of HC
was scored as follows: grade II, 18 (29%); grade III, 34 (55%);
and grade IV, 10 (16%). The median duration of HC was 30
days (range, 5–130 days).
The median hematologic parameters at diagnosis of HC were
as follows: hemoglobin concentration, 9.9 g/dL (range, 6.9–
14.8 g/dL); platelet count, platelets/L (range, 6–926.5 10
platelets/L); and white blood cell counts,9 9300 10 2.6 10
cells/L (range, 0– cells/L). Testing for BK viruria was915 10
undertaken in 57 episodes, although the timing and frequency
of testing were at the discretion of the investigator. In the
remaining 5 episodes the search for BKV was performed only
on blood ( ) or by cytologic testing ( ). Overall, thenp 4 np 1
finding of BK viruria anticipated HC in 14 episodes (25%),
coincided with the diagnosis of HC in 14 episodes (25%), and
was first detected after the diagnosis of HC in 29 episodes
(51%).
BK viremia was investigated in 39 episodes, and as for BK
viruria, the timing and frequency of testing were determined
at the discretion of the investigator. When tested, BK viremia
preceded HC in 8 episodes (21%), coincided with HC in 4
episodes (10%), and was first detected after the diagnosis of
HC in 27 episodes (69%). For the episodes of HC where BKV
replication preceded the clinical diagnosis, the median time
from first detection of BK viruria and BK viremia to devel-
opment of HC was 22 days (range, 1–61 days) and 11 days
(range, 1–35 days), respectively.
Treatment of HC. Table 1 summarizes the data regarding
cidofovir therapy. Hyperhydration was used in 56 patients
(90%), whereas bladder irrigation through a urethral catheter
was added in 33 patients (53%). Blood and platelet transfusions
were administered in 50 (81%) and 48 (77%) patients with
HC, with a median number of transfusions of 6.5 (range, 1–
210) and 12 (range, 1–276), respectively.
Fifty-seven patients (92%) received intravenous cidofovir,
with a median number of doses given of 4 (range, 1–15). The
starting dose of cidofovir was 0.5–1 mg/kg in 13 patients,
whereas the remaining 44 patients received a dose of 3–5 mg/
kg. Thirty-nine patients (68%) received probenecid as renal
protection. Cidofovir-related toxic effects were recorded in 18
(32%) of 57 patients treated with intravenous cidofovir and
were mainly related to the kidney. Moderate (grade I and II
World Health Organization toxicity score) to severe (grade III
and IV World Health Organization score) worsening of kidney
function on the basis of the creatinine value was observed in
6 patients, but no patient required hemofiltration or hemo-
dialysis after cidofovir administration. Only 1 patient had cy-
topenia related to cidofovir. Three patients died early of severe
complications after HSCT (i.e., 2 patients died of severe acute
GVHD and multiorgan failure on days 47 and 117, and 1
patient died of multiorgan failure on day 57). A fourth patient
died of progression of the underlying disease at day 163.
Five patients (8%) received intravesical cidofovir at a median
dose of 150 mg (range, 50–200 mg), with a median number
of 4 doses (range, 1–5). One of these experienced bladder
spasms during treatment that required antispasmodics and an-
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Figure 1. Modification of BK virus viremia over time expressed as log of viral load. The data correspond to the weeks of treatment with cidofovir.
CR, complete response; PR/F, partial response/failure.
algesics. In the remaining patients, no organ toxic effects were
reported.
Other potentially effective treatments for HC were used in
20 (32%) of 62 patients with HC as follows: hyperbaric oxygen
therapy, 8 patients; leflunomide, 4 patients; intrabladder in-
stillation of granulocyte-macrophage or granulocyte colony-
stimulating factor, 3 patients; application of platelet gel by cys-
toscopy, 3 patients; and foscarnet, 2 patients; with 1 treatment
each of ribavirin, lamivudine, ciprofloxacin, prostaglandin E,
and estrogens.
Clinical and virologic response to cidofovir. A CR was re-
corded in 38 (67%) of 57 patients with HC treated with in-
travenous cidofovir, whereas a PR was documented in 7 patients
(12%). No improvement or worsening was observed in 10
(18%) and 2 (3%) patients, respectively. Treatment with intra-
vesical cidofovir was associated with CR in 3 patients, PR in 1
patient, and no improvement in the remaining patient. Overall,
the response rate was not different in the 20 patients treated
with cidofovir plus other potentially effective treatments: in
this group, 11 were eventually classified as CR (55%) and 3 as
PR (15%).
Among 41 patients with CR, 29 had detectable BK viremia,
and 38 had BK viruria at HC diagnosis. Resolution of HC was
associated with the complete clearance of BK viremia in 22
(81%) of 27 patients who had at least 1 follow-up test after
starting cidofovir. The median time to BK viremia clearance
was 37 days (range, 7–102 days).
BK viruria test results became negative in 6 (20%) of 30
patients who had at least 1 follow-up test after starting cidofovir
therapy. In these patients, the median time to BK viruria clear-
ance was 161 days (range, 16–357 days).
Figure 1 shows the modification of BKV load according to
the type of clinical response and the time of BKV testing from
the start of HC. A reduction of 1 log and 3 logs in the median
value of BKV load was found in patients with a CR by 4 and
8 weeks after cidofovir treatment. The patients with PR or those
in whom cidofovir therapy failed showed an increase of BK
viremia by 4 weeks from the start of cidofovir administration.
Figure 2 shows the results of BK viremia in 10 patients who
obtained CR and who had quantitative BKV estimations on
blood samples before each cidofovir course. A reduction of2
logs of BKV load was documented in 7 patients (5 permanent
and 2 transient), whereas 3 patients did not have any modi-
fication of BKV load with cidofovir.
Risk factor analysis. Table 2 provides an analysis of factors
associated with CR in patients treated with intravenous cido-
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Figure 2. Modification of BK virus (BKV) viremia in 10 complete response (CR) patients who had BK viremia tested before every administration of
cidofovir. *Decrease in BKV load of 2 logs after cidofovir treatment.
fovir. In a univariate analysis, the following variables demon-
strated significance: the source of stem cells ( for bonePp .01
marrow or peripheral blood vs. cord blood), the use of total
body irradiation ( ), and the earlier recovery of poly-Pp .02
morphonuclear cells ( ). In multivariate analysis, thePp .045
factors that remained significant were the stem cell source
( ; relative risk, 7; 95% CI, 2–32) and the use of totalPp .01
body irradiation ( ; relative risk, 7; 95% CI, 1–38).Pp .03
TRM, OS, and event-free survival in patients with HC.
After a median follow-up of 287 days (range, 52 days to 4.7
years), 29 patients were alive. The total TRM rate was 50%
(95% CI, 35%–72%), whereas the 1-year OS rate was 39% (95%
CI, 25%–53%). Twenty-six (63%) of 41 patients with CR were
alive, compared with 3 (14%) of 21 patients with a PR or failure
of response ( ). The total TRM rate for patients withP ! .001
CR after cidofovir treatment was 40% (95% CI, 21%–78%)
versus 72% (95% CI, 54%–95%) for patients with a PR or
failure of response ( ).Pp .001
DISCUSSION
Although the pathogenesis of HC after allogeneic HSCT has
not been completely elucidated, there is evidence that this com-
plication is temporally correlated with engraftment, acute
GHVD, and high-level urinary BKV replication [6, 10, 11].
Because of frequent excretion of BKV in the urine of healthy
people and asymptomatic immunocompromised patients who
have undergone chemotherapy or HSCT, high BKV load in
urine (at least 3-log increase over baseline or a BKV load peak
108–109 copies/mL) has been suggested as a marker of late-
onset postengraftment HC [2, 3, 8]. Recently, a BKV load 103–
104 genomic copies/mL of blood has also been shown to be
associated with late-onset postengraftment HC [5, 6].
These findings have generated interest in the use of a specific
antiviral treatment for HC after HSCT in addition to the stan-
dard supportive measures used to date. Information on the use
of cidofovir for BKV-HC in HSCT recipients mainly stems from
case reports or case series [6, 17, 31]. Gorczynska et al. [18]
and Savona et al. [19] reported a clinical response of 80% and
84%, respectively, in 2 case series of 19 children and 19 adults
with resolution of BK viruria (by qualitative polymerase chain
reaction) in 32% of patients or a decrease of at least 1 log of
urinary BKV load in 47% of patients.
This article describes the largest series so far documenting
the potential role of cidofovir in the treatment of BKV-HC after
allogenic HSCT. In this series, male sex accounted for more
than 74% of episodes, which is in accordance with previous
reports [32, 33]. Most episodes occurred in the early posttrans-
plantation period or just after the postengraftment phase, sup-





CR to cidofovir Univariate P RR (95% CI) Multivariate P
Sex
Male 28/42 (67) …
Female 10/15 (67) 1.99 …
Age at HSCT, compared with median age (15.8 years)
Less than the median 24/31 (77) …
Greater than or equal to the median 14/26 (54) .06 …
Underlying disease
Malignant 32/50 (64) …
Nonmalignant 6/7 (86) .40 …
Status of diseasea
Controlled 28/45 (62) …
Uncontrolled 4/5 (80) .60 …
HLA matchingb
Match 24/32 (75) …
Mismatch 11/21 (52) …
Haplotype 2/3 (67) .20 …
Stem cell source
Bone marrow or peripheral blood 34/45 (76) …
Cord blood 4/12 (33) .01 7 (2–32) .01
Total body irradiation
Yesc 16/18 (89) …
Nod 22/39 (56) .02 7 (1–38) .03
Median TNC infused (bone marrow)b
Less than the median 5/8 (63) …
Greater than or equal to the median 8/9 (89) .30 …
Median of 34 CD cells infused (peripheral blood)
Less than the median 10/12 (83) …
Greater than or equal to the median 9/14 (64) .40 …
Median TNCs infused (cord blood)e
Less than the median 1/3 (33) …
Greater than or equal to the median 2/8 (25) 1.99 …
Polymorphonuclear cell recovery,f compared with the
median (17 days)
Less than the median 18/22 (82) …
Greater than or equal to the median 19/34 (56) .045 …
Platelet recovery,g compared with the median (27 days)
Less than the median 15/18 (83) …
Greater than or equal to the median 18/24 (75) .70 …
NOTE. CI, confidence interval; CR, complete response; HSCT, hematopoietic stem cell transplantation; RR, relative risk; TNC, total nucleated
cells.
a Only malignant disease.
b Data missing for 1.
c Among these patients, 1 received a low dose of 2 Gy, 1 received a single dose of 9.9 Gy, and all the remaining patients received a fractioned
dose of 12 Gy.
d Among these patients, 17 received a 3-drug regimen of the following drugs: busulfan, etoposide, fludarabine, melphalan, thiotepa, cyclo-
phosphamide, treosulfan, cytarabine; 21 received a 2-drug regimen of the following drugs: busulfan, cyclophosphamide, melphalan, fludarabine,
thiotepa, treosulfan, cytarabine, idarubicin, and one patient received a conditioning regimen with cyclophosphamide only. The median dose
(range) of drugs was as follows: busulfan, 12.8 mg/kg (9.6–20 mg/kg); etoposide, 40 mg/kg (2 patients); fludarabine, 150 mg/m2 (40–240 mg/
m2); melphalan, 140 mg/m2 (120–140 mg/m2); thiotepa, 10 mg/kg (8–15 mg/kg); cyclophosphamide, 120 mg/kg (40–200 mg/kg); treosulfan, 12
and 14 g/m2 (2 patients); cytarabine, 500 and 9000 mg/m2 (2 patients); and idarubicin, 24 mg/m2 (1 patient).
e Data missing for 2.
f Data on 56 engrafted patients.
g Data on 42 engrafted patients (data not available for 3 patients).
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porting the hypothesis that BKV-HC is a combination of 3
related phenomena (i.e., denudation of the urothelial transi-
tional cell layer by conditioning [34], massive high-level BKV
replication in the absence of virus-specific immune control,
and the early posttransplantation immune reconstitution [1,
11]). Given the retrospective nature of this study, it is not
possible to determine the value of BK viremia and BK viruria
in predicting the development of clinically overt HC. In the
subgroup of patients who were monitored prospectively, BK
viruria preceded HC earlier than BK viremia, with a median
of 22 versus 11 days. On the other hand, in our recent expe-
rience of 15 patients undergoing allogeneic HSCT who were
monitored prospectively during the first 3 months after trans-
plantation, BK viremia had a higher specificity and positive
predictive value than BK viruria of 82% and 67% versus 64%
and 50% [6].
CR was recorded in 66% of patients treated with cidofovir,
whereas an additional 13% obtained a PR with a clinical im-
provement. These results are comparable to those reported by
others in smaller series and support the view of a clinical benefit
of cidofovir treatment for BKV-HC. Regarding the virologic
response, the data clearly indicate that BK viremia may serve
as an early marker of cidofovir treatment failure by showing
significant increases in plasma BKV loads despite cidofovir
treatment. By contrast, in patients with CR the BKV load re-
mained low or even decreased over time. In the responding
patients, BKV was cleared from blood in 81% of HC episodes
versus 20% clearance of BKV from urine. The median time to
BKV clearance was 37 days for blood versus 161 days for urine.
Despite these findings, this study did not allow us to dem-
onstrate a definite role for cidofovir in curing BKV-related HC
because of its retrospective, uncontrolled design and the pres-
ence of heterogeneous variables that may have biased the re-
sults. Thus, a prospective investigation is still needed. Moreover,
we documented a different approach in the use of cidofovir
among different participating centers, so many questions, such
as the optimal dose and the best schedule and modality of
cidofovir administration, remain unresolved.
In the multivariate analysis, stem cell source was significantly
associated with a better probability of predicting CR after in-
travenous cidofovir, being inferior for patients receiving cord
blood. We speculate that the absence of BKV-specific immunity
in the donor graft may predispose the patient to a persistent
BKV replication and maintain the mechanism of immune at-
tack on the bladder mucosa during the early phase of immune
recovery. On the other hand, the positive effect of a condi-
tioning regimen containing total body irradiation on the re-
sponse rate to cidofovir is not easily explained and deserves
further investigation. Interestingly, the lack of resolution of
BKV-HC was associated with inferior OS and higher TRM rates,
confirming that vesical bleeding is also a marker of poor out-
come after allogeneic HSCT [7, 35].
Overall, cidofovir was found to be safe and tolerable, with
moderate to severe renal toxic effects observed in only a few
patients. This finding suggests that the use of probenecid or a
low-dose cidofovir schedule reduces the well-known risk of
renal toxic effects caused by cidofovir. Intravesical administra-
tion of cidofovir seemed to be effective, but the number of
patients was even smaller, so any conclusion appears premature
at this point, including whether intravesical cidofovir represents
an effective alternative to intravenous administration, especially
in patients at high risk of renal complications or toxic effects
[36].
In conclusion, cidofovir for the treatment of BKV-HC seems
to be well tolerated and associated with resolution or significant
clinical improvement. A reduction in BKV load by 1–3 logs is
observed in most responding patients. Additional prospective,
randomized studies are needed to confirm the efficacy of ci-
dofovir in treating BKV-HC.
THE EUROPEAN GROUP FOR BLOOD AND
MARROW TRANSPLANTATION
The EBMT centers and investigators contributing patients in-
cluded in this analysis are as follows (the number of patients
who underwent transplantation in each center is in paren-
theses): Policlinico Tor Vergata, Rome, Italy, Angela Beltrame,
William Arcese (5 patients); Sant Eugenio Hospital, Rome, Italy,
Andrea Tendas, Paolo De Fabritiis (5 patients); Bambino Gesu`
Hospital, Rome, Italy, Maurizio Caniglia, Giulio De Rossi (2
patients); Institute G. Gaslini, Genoa, Italy, Maura Faraci, Gior-
gio Dini (7 patients); Wroclaw Medical University, Wroclaw,
Poland, Joanna Owoc-Lempach, Alicja Chybicka (6 patients);
Evangelismos Hospital, Athens, Greece, Ioannis Baltadakis,
Dimitrios Karakasis (5 patients); Hoˆpital Robert Debre, Paris,
France, Jean Hughes Dalle (5 patients); Medical Park Hospitals,
Antalya, Turkey, Yener Koc (5 patients); University Hospital,
Basel, Switzerland, Nina Khanna, Hans H. Hirsch and Alois
Gratwohl (4 patients); University Hospital, Lund, Sweden, Jacek
Toporski, Stig Lenhoff (3 patients); University of Padua, Padua,
Italy, Simone Cesaro, Chiara Messina (3 patients); University
Hospital, Bydgoszcz, PL, Jan Styczynski, Mariusz Wysocki (3
patients); Akdeniz University Medical School, Antalya, Turkey,
M. Akif Yesilipek (2 patients); Medizinische und Poliklinik II,
Wu¨rzburg, Germany, Werner Heinz, Herman Einsele (2 pa-
tients); Vilnius University Childrens Hospital, Vilnius, Lithu-
ania, Jelena Rascon (1 patient); Klinik fu¨r Knochenmarktrans-
plantation, Idar-Oberstein, Germany, Ludwig Kraut, Axel A.
Fauser (1 patient); Hopital E. Herriot, Lyon, France, Mauricette
Michallet, A Thiebaut, Nicole Raus (1 patient); Hospital Clı´n-
ico, Salamanca, Spain, Lucia Lopez Corral, Dolores Caballero
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(1 patient); and Charite´ Universita¨tsmedizin Berlin, Berlin,
Germany, Stefan Neuburger, Renate Arnold (1 patient)
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